
Keywords: CD; Crohn's disease; Anti-TNF-α; anti-tumor necrosis factor-α; IFX; infliximab; PCDAI; Pediatric Crohn's Disease Activity Index; ATI; anti-infliximab-antibodies; PDAI; Perianal Crohn's Disease Activity Index; QoL; quality of life; UC; ulcerative colitis